Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
50 Pulmonary Hypertension Trials
Power is an online platform that helps thousands of Pulmonary Hypertension patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:PH WHO Groups 1, 3, 4, Others
230 Participants Needed
Sotatercept for Pulmonary Hypertension
Columbus, OhioThis trial tests sotatercept, a medication aimed at improving heart and lung function in adults with a specific type of heart failure. It works by reducing resistance in lung blood vessels, helping the heart pump blood more easily.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:PH WHO Group 1, Lung Disease, Cardiovascular, Others
Must Not Be Taking:PAH-specific Therapies
150 Participants Needed
Ralinepag for Pulmonary Arterial Hypertension
Columbus, OhioThis trial is testing ralinepag, a medication being developed for the treatment of pulmonary arterial hypertension (PAH). It aims to see if adding ralinepag to their usual treatments can improve their condition. The medication works by relaxing and opening up the blood vessels in the lungs, which can lower the pressure and improve blood flow.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Liver Disease, Renal Insufficiency, Malignancy, Others
Must Be Taking:Endothelin Antagonists, PDE5 Inhibitors
1000 Participants Needed
Milrinone for Congenital Diaphragmatic Hernia
Columbus, OhioThis trial is testing if milrinone, a medicine that helps the heart and lungs, can improve oxygen levels in newborns with severe lung and heart problems due to CDH. These babies often don't get better with usual treatments. The goal is to see if milrinone can safely help these babies breathe easier. Milrinone is used in up to 30% of CDH infants across the United States, but no studies have tested its effectiveness or safety in these newborns.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:0+
Sex:All
66 Participants Needed
Ralinepag for Pulmonary Arterial Hypertension
Columbus, OhioThis trial tests ralinepag, a medication for lung disease, on patients with PAH who participated in earlier research. It aims to improve blood flow in the lungs by relaxing blood vessels and reducing pressure.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:18 - 75
Sex:All
1000 Participants Needed
Aria CV System for Pulmonary Arterial Hypertension
Columbus, OhioThis trial is testing a new device called the Aria CV PH System, which helps manage high blood pressure in the lungs and supports heart function. It is aimed at patients with pulmonary hypertension and related heart issues. The study will check if the device is safe and effective over a period of several months to a few years.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Renal Insufficiency, Scleroderma, Others
Must Be Taking:PH Specific Medications
30 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Columbus, OhioThis trial is testing sotatercept, a medication for high blood pressure in the lungs, in adults with PAH who have completed earlier studies. It aims to see if the medication is safe and effective over a long period. Sotatercept helps lung blood vessels function better, reducing lung pressure. Sotatercept has shown promising results in earlier studies for reducing lung pressure and improving exercise tolerance in patients with pulmonary arterial hypertension (PAH).
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Missed Doses, Others
Must Be Taking:PAH Therapy
700 Participants Needed
Treprostinil for Pulmonary Arterial Hypertension
Columbus, OhioThe primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Amphetamine Use, Hepatic Impairment, Others
Must Be Taking:Endothelin Antagonists, PDE-5 Inhibitors
50 Participants Needed
Macitentan for Pulmonary Hypertension
Columbus, OhioThis trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:1 - 17
Sex:All
165 Participants Needed
Seralutinib for Pulmonary Arterial Hypertension
Columbus, OhioThis trial is testing a medication called seralutinib to see if it can help people with a specific type of lung disease (PAH) improve their ability to exercise. The medication works by blocking signals that cause the blood vessels in the lungs to tighten and narrow. Seralutinib is delivered via inhalation and is being developed for patients with pulmonary arterial hypertension. The goal is to see if this can reduce lung pressure and delay worsening of the disease.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis, Hypertension, Others
Must Be Taking:Endothelin Antagonists, PDE5 Inhibitors
350 Participants Needed
Inhaled Vardenafil for Pulmonary Arterial Hypertension
Columbus, OhioThis trial is testing an inhaled medication called RT234. It aims to help people with pulmonary arterial hypertension (PAH) breathe better and exercise more easily. The medication works by widening the blood vessels in the lungs, making it easier for the heart to pump blood. RT234 is being developed to improve exercise tolerance and symptoms in patients with PAH.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 80
Sex:All
42 Participants Needed
GB002 for Pulmonary Arterial Hypertension
Columbus, OhioThis trial will study the long-term effects of GB002 (seralutinib) in patients who were part of an earlier study for Pulmonary Arterial Hypertension (PAH). Seralutinib is a new treatment developed for PAH and has shown better results compared to another treatment in early studies.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Hypertension, Heart Disease, Infections, Others
Must Be Taking:PAH Therapies
100 Participants Needed
Riociguat for Pulmonary Hypertension Due to Heart Failure
Fairfield, OhioThe aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 80
Sex:All
202 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Cincinnati, OhioThis trial is testing a medication called sotatercept to see if it is safe and how it acts in children with high blood pressure in the lungs, who are already on standard treatments. The study will last for several months. Sotatercept has shown promise in improving exercise tolerance in adults with pulmonary arterial hypertension.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:1 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Left-sided Heart Disease, Eisenmenger Syndrome, Pulmonary Veno-occlusive Diseases, Coronary Disease, Others
Must Be Taking:PDE5 Inhibitors, ERAs, SGCS, Prostanoids
42 Participants Needed
Selexipag for Pulmonary Arterial Hypertension
Cincinnati, OhioThe purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2 - 17
Sex:All
138 Participants Needed
Inhaled Treprostinil for Pulmonary Arterial Hypertension
Cincinnati, OhioThe primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
92 Participants Needed
Mono vs Dual Therapy for Pediatric Pulmonary Hypertension
Cincinnati, OhioThe investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:3 - 18
Sex:All
Key Eligibility Criteria
Disqualifiers:Syncope, RV Failure, Pregnancy, Others
Must Not Be Taking:Cyclosporine, Glyburide, CYP3A Inhibitors, Others
100 Participants Needed
High-Dose Macitentan for PAH
Cincinnati, OhioThis trial is testing if a higher dose of macitentan can better help patients with pulmonary arterial hypertension by improving blood flow in their lungs. Macitentan has shown promise in helping patients by slowing down the disease and improving their health.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
935 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Cincinnati, OhioResearchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs.
The goal of the study is to learn:
* What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this trial.
* About the safety of sotatercept and if people tolerate it
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Hypertension, Coronary Artery Disease, Obstructive Sleep Apnea, Others
160 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Cincinnati, OhioThis trial is testing sotatercept, a new medication, to see if it can help people with a specific type of high blood pressure in the lungs (PAH) when added to their usual treatment. The study focuses on patients who are newly diagnosed and at higher risk of their condition worsening. Sotatercept aims to reduce the pressure in the lung's blood vessels, potentially slowing down disease progression. Sotatercept has shown significant reduction in pulmonary vascular resistance and maintained clinical efficacy in previous studies.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
444 Participants Needed
KER-012 for Pulmonary Arterial Hypertension
Cincinnati, OhioThis trial is testing KER-012, a new injectable medication, in adults with a specific type of high blood pressure in the lungs. The goal is to see if it can lower lung blood pressure and help patients walk better.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
113 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Cincinnati, OhioThis trial is testing sotatercept added to current treatments for patients with severe PAH who are at high risk of death. The goal is to see if it can lower lung blood pressure and improve patient outcomes. Sotatercept, which modulates bone morphogenic protein receptor type 2 (BMPR2) signaling, showed promising results in earlier studies.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
172 Participants Needed
FETO for Congenital Diaphragmatic Hernia
Cincinnati, OhioTracheal occlusion IDE approved by FDA for congenital diaphragmatic hernia fetuses.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 50
Sex:Female
Key Eligibility Criteria
Disqualifiers:Multifetal Pregnancy, Chromosomal Abnormalities, Others
40 Participants Needed
TX000045 for Pulmonary Hypertension
Toledo, OhioTX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 83
Sex:All
Key Eligibility Criteria
Disqualifiers:Significant Lung Disease, Cardiovascular, Others
Must Not Be Taking:Vasoactive Drugs
180 Participants Needed
LAM-001 for Pulmonary Hypertension
Cleveland, OhioThis is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Hypertension, Heart Failure, Coronary Disease, Others
Must Be Taking:PAH Therapy
15 Participants Needed
Mechanical Circulatory Support for Heart Failure
Cleveland, OhioThe purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Inotrope Use, Thyroid Disease, Valvular Heart Disease, Others
Must Be Taking:Betablockers, ACE Inhibitors, Diuretics, SGLT2 Inhibitors
850 Participants Needed
Nutrition and Exercise for Pulmonary Arterial Hypertension
Cleveland, OhioThe purpose of this study is to investigate the extent to which diet and exercise may improve PAH through the modulation of insulin sensitivity. The central hypothesis is that dysregulated glucose metabolism elicits a response in PAH patients that can be modified by exercise and diet, thereby leading to improvements in pulmonary vascular disease.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:All
34 Participants Needed
Inhaled sGC Stimulator for Pulmonary Hypertension and COPD
Lexington, KentuckyResearchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take MK-5475 can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Group 1 PAH, Sleep Apnea, Heart Disease, Renal Insufficiency, Cancer, Others
Must Be Taking:PDE5 Inhibitors
120 Participants Needed
Metformin for Pulmonary Hypertension
Pittsburgh, PennsylvaniaThe main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
10 Participants Needed
L606 Inhalation Suspension for Pulmonary Arterial Hypertension
Pittsburgh, PennsylvaniaThis trial tests a new medication called L606 in patients with specific types of lung disease. It aims to see if L606 is safe, helps patients breathe better, and improves their quality of life compared to an existing treatment called Tyvaso. LIQ861 is a novel dry-powder formulation of treprostinil, similar to the inhaled, nebulized treprostinil (Tyvaso®).
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 80
Sex:All
28 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do Pulmonary Hypertension clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Pulmonary Hypertension clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Pulmonary Hypertension trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Pulmonary Hypertension is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Pulmonary Hypertension medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Pulmonary Hypertension clinical trials ?
Most recently, we added Supplemental Oxygen for Pulmonary Hypertension, Empagliflozin + Ranolazine for Right Ventricular Dysfunction and Mechanical Circulatory Support for Heart Failure to the Power online platform.